Fig 1.
Dynamics of vaccination in the Czech Republic.
Specific days in which vaccination was open to an age group or professional or other category are specified in S1 Table in S2 File.
Fig 2.
Vaccine effectiveness against infection.
Vaccine-acquired immunity against infection with respect to the delay from the full vaccine application, including the effect of a booster vaccine dose.
Fig 3.
Estimating potential statistical differences between the vaccines.
A Z-test has been performed to test for those differences. For each pair of covariates (each covariate is characterized by the vaccine and the time interval since completing the corresponding vaccination scheme), a color is assigned to indicate a degree of statistical significance: blue for 1% (|Z| > 2.576), red for 5% (2.576 ≥ |Z| > 1.960), and gray for |Z| ≤ 1.960. Moreover, only pairs with positive values of the test statistic Z are plotted, indicating a positive difference between a respective y-axis covariate and x-axis covariate (values symmetric around the diagonal are negative with the same absolute value). The axis labels are composed of a capital letter (P = BNT162b2 vaccine, M = mRNA-1273 vaccine, A = ChAdOx1-S vaccine, and J = Ad26.COV2-S vaccine) and a number range (months since full vaccination) or ‘boost’ (3rd vaccine dose).
Table 1.
Estimated increase of breakthrough infection hazard ratios (HRs) in times of the SARS-CoV-2 delta variant dominance for age groups having started vaccination in the same month.
Table 2.
Vaccine effectiveness against infection after administering the booster vaccine dose for various possible combinations of primary (columns) and booster (rows) vaccines (with the exception of Janssen due to insufficient data).
Hazard ratios (HRs) are given.
Fig 4.
Infection-acquired immunity against reinfection with respect to the delay from the prior infection.
The delay 0–2 months is not considered as a new infection which implies 100% effectiveness by definition.